NCT04353362

Brief Summary

Context and Aims: Several studies have demonstrated an association between obesity, periodontitis, and exercise. This study aimed to investigate the effects of regular exercise on obese women with periodontal disease, using serum, saliva, and gingival crevicular fluid (GCF) samples. Settings and Design: A before-after study design was adopted to evaluate the effects of 12 weeks of regular exercise on obese women grouped according to periodontal status, without a control group (no exercise). Methods and Material: The study sample comprised fifteen patients without periodontitis (NP group) and 10 patients with chronic periodontitis (CP group), from whom periodontal parameters were measured and serum, saliva, and GCF samples were collected. Body mass index (BMI), anthropometric measurements, somatotype-motoric tests, and maximal oxygen consumption (VO2max) were recorded at baseline and after exercise. Statistical analysis used: MedCalc was used for statistical analysis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
74

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Apr 2017

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2017

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 2, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 10, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 15, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 20, 2020

Completed
Last Updated

April 20, 2020

Status Verified

April 1, 2020

Enrollment Period

2.8 years

First QC Date

April 15, 2020

Last Update Submit

April 16, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Probing depth

    Probing depth was recorded at the baseline, first, third, and sixth month. The changes were evaluated among and between groups.

    6-months

Secondary Outcomes (1)

  • Clinical attachment loss

    6-months

Study Arms (2)

Ofloxacin group

EXPERIMENTAL
Drug: Ofloxacin

Amoxicillin plus Metronidazole group

ACTIVE COMPARATOR
Drug: AmoxicillinDrug: Metronidazole

Interventions

400 mg, 1 time per day for 5 days

Ofloxacin group

500 mg, 3 times per day for 7 days

Amoxicillin plus Metronidazole group

500 mg, 3 times per day, for 7 days

Amoxicillin plus Metronidazole group

Eligibility Criteria

Age20 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • The periodontal diagnosis of participants with generalized periodontitis stage III-IV/grade C. Systemically healthy participants with generalized periodontitis were enrolled if they were between 18 and 40 years of age, and had no allergies to penicillin, metronidazole or quinolones, a history of antibiotic therapy or periodontal therapy within the preceding six months

You may not qualify if:

  • Subjects were excluded if they had any known systemic diseases or conditions that can/could influence the periodontal status, allergies to quinolones, penicillin or metronidazole, a history of antibiotic therapy, or periodontal treatment within the preceding six months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Begum Alkan

Istanbul, 34230, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Periodontitis

Interventions

OfloxacinAmoxicillinMetronidazole

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Fluoroquinolones4-QuinolonesQuinolonesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsAmpicillinPenicillin GPenicillinsbeta-LactamsLactamsAmidesOrganic ChemicalsSulfur CompoundsNitroimidazolesNitro CompoundsImidazolesAzolesHeterocyclic Compounds, 1-Ring

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

April 15, 2020

First Posted

April 20, 2020

Study Start

April 1, 2017

Primary Completion

January 2, 2020

Study Completion

March 10, 2020

Last Updated

April 20, 2020

Record last verified: 2020-04

Locations